Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 104-108

  Oh, J ^a   Chung, H ^a   Park, S I ^a   Yi, S J ^a   Jang, K ^a   Kim, A H ^a   Yoon, J ^a   Cho, J Y ^a   Yoon, S H ^a   Jang, I J ^a   Yu, K S ^a   Chung, J Y ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Drug transporter; MATE; Metformin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

GLUCOSE; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; PYRIMETHAMINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; MATE1 PROTEIN, HUMAN; ORGANIC CATION TRANSPORTER;

ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROSPRAY MASS SPECTROMETRY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; LETTER; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PHARMACODYNAMICS; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; URINARY EXCRETION; ADULT; BLOOD; CROSSOVER PROCEDURE; DRUG EFFECTS; DRUG INTERACTION; GLUCOSE TOLERANCE TEST;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DRUG INTERACTIONS; GLUCOSE TOLERANCE TEST; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; PYRIMETHAMINE;

EID: 84955203998     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12577     Document Type: Article

References (17)

1. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005; 7: 654-665.
2. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-260.
3. Sambol NC, Chiang J, O'Conner M etal. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996; 36: 1012-1021.
4. He R, Zhang D, Lu W etal. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Diabetes Res Clin Pract 2015; 109: 57-63.
5. Kusuhara H, Ito S, Kumagai Y etal. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011; 89: 837-844.
6. Ito S, Kusuhara H, Kuroiwa Y etal. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010; 333: 341-350.
7. Jacobson JM, Davidian M, Rainey PM, Hafner R, Raasch RH, Luft BJ. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob Agents Chemother 1996; 40: 1360-1365.
8. Ito K, Chiba K, Horikawa M etal. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 2002; 4: E25.
9. Coleman MD, Mihaly GW, Edwards G, Ward SA, Howells RE, Breckenridge AM. Pyrimethamine pharmacokinetics and its tissue localization in mice: effect of dose size. J Pharm Pharmacol 1985; 37: 170-174.
10. Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 2002; 30: 861-868.
11. Napolitano A, Miller S, Nicholls AW etal. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014; 9: e100778.
12. Wood RC, Hitchings GH. Effect of pyrimethamine on folic acid metabolism in streptococcus faecalis and Escherichia coli. J Biol Chem 1959; 234: 2377-2380.
13. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis 2011; 34: 75-81.
14. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J Mol Endocrinol 2001; 27: 85-91.
15. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011; 13(Suppl. 1): 126-132.
16. Cho SK, Yoon JS, Lee MG etal. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011; 89: 416-421.
17. Cho SK, Kim CO, Park ES, Chung JY. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol 2014; 78: 1426-1432.